Shanghai Stock Exchange

Shanghai, China

Shanghai Stock Exchange

Shanghai, China
SEARCH FILTERS
Time filter
Source Type

SHANGHAI, April 27, 2017  /PRNewswire/ -- China Eastern Airlines Corporation Limited (the "Company") (NYSE: CEA; HKSE: 0670; SSE: 600115) announces that the Company's annual report for the 2016 fiscal year filed with the Securities and Exchange Commission on April 27, 2017 can be accessed via the following link: https://www.sec.gov/Archives/edgar/data/1030475/000114420417022414/v464319_20f.htm on SEC website or http://en.ceair.com/about/dqbg_ny_2016/t2017427_30703.html on Company's website A paper copy of the Company's complete audited annual report will be provided to any shareholder without charge, upon written request to Investor Relations, Secretary Office of the Board of Directors, China Eastern Airlines Corporation Limited at Kong Gang San Road, Number 92, Shanghai 200335, the People's Republic of China. China Eastern Airlines Corporation Limited is one of the three largest airline companies in China. The Company was established as a joint stock limited company incorporated in the People's Republic of China on April 4, 1995. The Company successfully offered its American Depositary Shares ("ADSs") and H Shares in New York and Hong Kong, respectively, and its ADSs and H Shares were listed on the New York Stock Exchange, Inc. and The Stock Exchange of Hong Kong Limited on February 4, 1997 and February 5, 1997, respectively. The Company's A shares were listed on the Shanghai Stock Exchange on November 5, 1997. For further information, please visit the Company website: http://www.ceair.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/annual-report-on-form-20-f-for-fiscal-year-2016-of-china-eastern-airlines-corporation-limited-available-300447153.html


News Article | April 28, 2017
Site: en.prnasia.com

HONG KONG, April 28, 2017 /PRNewswire/ -- Guangshen Railway Company Limited ("Guangshen Railway" or the "Company") (HKEx Share Code: 525; SSE Share Code: 601333; American Depositary Shares ("ADS") Ticket Symbol: GSH) announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2016 with the U.S. Securities and Exchange Commission on April 26, 2017. The annual report can be accessed on Guangshen Railway's investor relations website at http://www.gsrc.com/en/down_list.php?classid=001. The Company will provide hard copies of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Guangshen Railway Company Limited was established in March 1996. The H shares and ADS issued by the Company were listed on The Stock Exchange of Hong Kong Limited and the New York Stock Exchange in May 1996. In December 2006, the Company returned to the A share market and successfully listed its shares on the Shanghai Stock Exchange. The Company is currently the only PRC railway enterprise with its shares listed on the Shanghai, Hong Kong and New York stock exchanges. The Company is mainly engaged in railway passenger and freight transportation businesses, the Hong Kong Trough Train passenger services in cooperation with MTR Corporation Limited, and management services for commissioned transportation for other railway companies in PRC.  As of December 31, 2016, there were 253 pairs of passenger trains in the operation area of the Company according to the then train schedule, including 102 pairs of intercity high-speed passenger trains between Guangzhou and Shenzhen (including 94 pairs of inter-city trains between Guangzhou East to Shenzhen (including 20 stand-by pairs), 8 pairs of Guangzhou East to the Chaozhou-Shantou cross-network EMU trains), 13 pairs of Hong Kong Through Trains (including 11 pairs of Canton-Kowloon Through Trains, 1 pair of Zhaoqing-Kowloon Through Trains and 1 pair of Beijing/Shanghai-Kowloon Through Trains) and 138 pairs of long-distance trains (including 10 pairs of Guangzhou-Foshan-Zhaoqing intercity trains, 3 pairs of Guangzhou to Guilin North, NaningEast and Guiyang North cross-network EMU trains) For more information, please visit Guangshen Railway at http://www.gsrc.com/en/index.php. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/guangshen-railway-filed-2016-annual-report-on-form-20-f-300448029.html


Annual Report on Form 20-F for Fiscal Year 2016 of Aluminum Corporation of China Limited Now Available Aluminum Corporation of China Limited (the "Company"; NYSE "ACH"; SEHK "2600"; SSE "601600") announces that the Company's annual report for the 2016 fiscal year filed with the SEC on April 18, 2017 can be accessed via the following link: http://tinyurl.com/l2m4cq8 A paper copy of the Company's complete annual report will be provided to any shareholder without charge upon written request to Aluminum Corporation of China Limited at No. 62 North Xizhimen Street, Haidian District, Beijing, PRC 100082. Background information: Aluminum Corporation of China Limited is a leading enterprise in non-ferrous metal industry in China. The scope of business of the Company primarily includes bauxite and coal mining, alumina refining, primary aluminum smelting, trading of alumina, primary aluminum, other non-ferrous metal products, coal products and raw and ancillary materials in bulk and power generation. The Company was established as a joint stock limited company incorporated in the People's Republic of China. The Company's American Depository Shares and H Shares are listed on the New York Stock Exchange, Inc. and the Stock Exchange of Hong Kong Limited respectively. The Company's A Shares are listed on the Shanghai Stock Exchange. For further queries, please visit http://www.chalco.com.cn


News Article | April 28, 2017
Site: www.prnewswire.com

Guangshen Railway Company Limited was established in March 1996. The H shares and ADS issued by the Company were listed on The Stock Exchange of Hong Kong Limited and the New York Stock Exchange in May 1996. In December 2006, the Company returned to the A share market and successfully listed its shares on the Shanghai Stock Exchange. The Company is currently the only PRC railway enterprise with its shares listed on the Shanghai, Hong Kong and New York stock exchanges. The Company is mainly engaged in railway passenger and freight transportation businesses, the Hong Kong Trough Train passenger services in cooperation with MTR Corporation Limited, and management services for commissioned transportation for other railway companies in PRC.  As of December 31, 2016, there were 253 pairs of passenger trains in the operation area of the Company according to the then train schedule, including 102 pairs of intercity high-speed passenger trains between Guangzhou and Shenzhen (including 94 pairs of inter-city trains between Guangzhou East to Shenzhen (including 20 stand-by pairs), 8 pairs of Guangzhou East to the Chaozhou-Shantou cross-network EMU trains), 13 pairs of Hong Kong Through Trains (including 11 pairs of Canton-Kowloon Through Trains, 1 pair of Zhaoqing-Kowloon Through Trains and 1 pair of Beijing/Shanghai-Kowloon Through Trains) and 138 pairs of long-distance trains (including 10 pairs of Guangzhou-Foshan-Zhaoqing intercity trains, 3 pairs of Guangzhou to Guilin North, NaningEast and Guiyang North cross-network EMU trains) For more information, please visit Guangshen Railway at http://www.gsrc.com/en/index.php. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/guangshen-railway-filed-2016-annual-report-on-form-20-f-300448029.html


News Article | May 11, 2017
Site: en.prnasia.com

NEW ORLEANS, May 11, 2017 /PRNewswire/ -- Environmental officials and business executives from China and the United States have called for closer technology cooperation in the face of rising environmental challenges to the world's two largest economies. At the Forth China-U.S. Environmental Industries Forum (EIF), Ling Jinming, executive director of Beijing GeoEnviron Engineering & Technology Inc. (BGE) said that company would like to take the opportunity to expand cooperation with U.S. counterparts for further industrial upgrades. As a leading player in the provision of environmental system services as well as environmental remediation, BGE has been active in exploring Chinese and overseas markets in the past years. It has participated in a series of high-profile environmental programs, including a project of remediating pollution in Tengger Desert in northern China's Inner Mongolia, as well as a contamination control project in a mine in southeastern China's Fujian province, Ling told officials and business leaders at the forum. As an effort to expand international presence, BGE has worked on remediation projects in Kazakhstan, Indonesia, Mongolia, Laos and Myanmar. It has also established research centers with companies from Switzerland and Germany, as well as a joint company with TRS, an American remediation technology and equipment provider, Ling said. The forum, co-chaired by the U.S. Department of Commerce, Chinese Ministry of Environmental Protection (MEP) and the U.S. Environmental Protection Agency, is an important platform for growing cooperation in clean technology between China and the US, where industry counterparts of the two countries can discuss a variety of technical, trade and policy issues. Originally founded in 1992, BGE, whose predecessor was Lining Engineering Department of the Institute of High Energy Physics of Chinese Academy of Science, has been committed in environment technology researches and providing solutions to pollution prevention and control. BGE was listed on the A-share (603588.SH) at Shanghai Stock Exchange on December 29th. 2014. It has about 1400 employees with total assets of 4.4 billion Yuan. BGE's main businesses include environmental remediation, urban and industrial environments, such as the soil remediation, groundwater remediation, hazardous waste treatment, industrial solid waste treatment, industrial waste water treatment, sludge disposal as well as the power generation by waste incineration. It also provides project contracting, investment operations and technical services to government and business users. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/beijing-geoenviron-participates-in-china-us-environmental-industries-forum-300456071.html


News Article | May 11, 2017
Site: www.prnewswire.com

The vertical barrier system, which could effectively control, separate and block contaminants from polluting underground water and soils in dredge mining operations, is one of the core technologies independently developed by BGE (XSHG: 603588), a leading player in the industry that provides advanced pollution prevention and treatment solutions in China. The technology, which is expected to become the most eco-friendly solution to the rising potential threats caused by leakage of toxic and harmful obstacles in abandoned mines as well as aging refuse landfills in the cities, has been honored the third prize of Science and Technology of Environmental Protection, and selected on the list of 2015 National Key Environmental Protection Practical Technology. So far, the vertical barrier technology has been successfully used in a series of projects in China, including Zijin Mining Project in Fujian province and Chihong Zn&Ge project in Yunnan province, which the vertical barrier wall was used to contain groundwater flow and migration of metal ion, as well as Jingjiang Project in Jiangsu province to contain groundwater flow and migration of organic chemicals. Originally founded in 1992, BGE, whose predecessor was Lining Engineering Department of the Institute of High Energy Physics of Chinese Academy of Science, has been committed in environment technology researches and providing solutions to pollution prevention and control. BGE was listed on the A-share (XSHG: 603588) at Shanghai Stock Exchange on December 29th. 2014. It has about 1400 employees with total assets of 4.4 billion Yuan. At present, BGE owns 138 patented technologies, 6 software copyrights. BGE has hosted or participated in the setting of 38 national and professional standards and technical specification. As a member of International Association of Geosynthetic Installers (IAGI) and International Geosynthetics Society (IGS) since 2006, BGE has been a pioneer in exploring the international market with completing projects in Kazakhstan, Indonesia, Mongolia, Laos and Myanmar. BGE has also set up an branch together with the Indonesian government to promote local industrial upgrading by BGE's advanced incineration technology. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/beijing-geoenvirons-key-technology-awarded-as-top-100-in-china-300455147.html


News Article | May 11, 2017
Site: en.prnasia.com

BEIJING, May 11, 2017 /PRNewswire/ -- An advanced control system against mining contamination, independently developed by Beijing GeoEnviron Engineering & Technology Inc (BGE), has been listed as one of the 3iPET TOP 100 environmental protection technologies supported by Chinese Ministry of Environmental Protection. The 3iPET Top 100 Environmental Protection Technologies Contests is launched by Foreign Economic Cooperation Office (FECO) of Ministry of Environmental Protection (MEP) of China. An efforts as China is exploring the best technologies and cooperation networks among official and private organizations and companies, both domestic and international, in the hope to provide the best opportunities to promote technologies to solve environmental problems in China and around the world. The vertical barrier system, which could effectively control, separate and block contaminants from polluting underground water and soils in dredge mining operations, is one of the core technologies independently developed by BGE (XSHG: 603588), a leading player in the industry that provides advanced pollution prevention and treatment solutions in China. The technology, which is expected to become the most eco-friendly solution to the rising potential threats caused by leakage of toxic and harmful obstacles in abandoned mines as well as aging refuse landfills in the cities, has been honored the third prize of Science and Technology of Environmental Protection, and selected on the list of 2015 National Key Environmental Protection Practical Technology. So far, the vertical barrier technology has been successfully used in a series of projects in China, including Zijin Mining Project in Fujian province and Chihong Zn&Ge project in Yunnan province, which the vertical barrier wall was used to contain groundwater flow and migration of metal ion, as well as Jingjiang Project in Jiangsu province to contain groundwater flow and migration of organic chemicals. Originally founded in 1992, BGE, whose predecessor was Lining Engineering Department of the Institute of High Energy Physics of Chinese Academy of Science, has been committed in environment technology researches and providing solutions to pollution prevention and control. BGE was listed on the A-share (XSHG: 603588) at Shanghai Stock Exchange on December 29th. 2014. It has about 1400 employees with total assets of 4.4 billion Yuan. At present, BGE owns 138 patented technologies, 6 software copyrights. BGE has hosted or participated in the setting of 38 national and professional standards and technical specification. As a member of International Association of Geosynthetic Installers (IAGI) and International Geosynthetics Society (IGS) since 2006, BGE has been a pioneer in exploring the international market with completing projects in Kazakhstan, Indonesia, Mongolia, Laos and Myanmar. BGE has also set up an branch together with the Indonesian government to promote local industrial upgrading by BGE's advanced incineration technology. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/beijing-geoenvirons-key-technology-awarded-as-top-100-in-china-300455147.html


News Article | May 11, 2017
Site: www.prnewswire.com

As a leading player in the provision of environmental system services as well as environmental remediation, BGE has been active in exploring Chinese and overseas markets in the past years. It has participated in a series of high-profile environmental programs, including a project of remediating pollution in Tengger Desert in northern China's Inner Mongolia, as well as a contamination control project in a mine in southeastern China's Fujian province, Ling told officials and business leaders at the forum. As an effort to expand international presence, BGE has worked on remediation projects in Kazakhstan, Indonesia, Mongolia, Laos and Myanmar. It has also established research centers with companies from Switzerland and Germany, as well as a joint company with TRS, an American remediation technology and equipment provider, Ling said. The forum, co-chaired by the U.S. Department of Commerce, Chinese Ministry of Environmental Protection (MEP) and the U.S. Environmental Protection Agency, is an important platform for growing cooperation in clean technology between China and the US, where industry counterparts of the two countries can discuss a variety of technical, trade and policy issues. Originally founded in 1992, BGE, whose predecessor was Lining Engineering Department of the Institute of High Energy Physics of Chinese Academy of Science, has been committed in environment technology researches and providing solutions to pollution prevention and control. BGE was listed on the A-share (603588.SH) at Shanghai Stock Exchange on December 29th. 2014. It has about 1400 employees with total assets of 4.4 billion Yuan. BGE's main businesses include environmental remediation, urban and industrial environments, such as the soil remediation, groundwater remediation, hazardous waste treatment, industrial solid waste treatment, industrial waste water treatment, sludge disposal as well as the power generation by waste incineration. It also provides project contracting, investment operations and technical services to government and business users. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/beijing-geoenviron-participates-in-china-us-environmental-industries-forum-300456071.html


Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced the signature of a strategic agreement with Tasly Pharmaceutical (Shanghai: 600535), a group ranked amongst China’s top 10 listed pharmaceutical companies. This partnership includes three axes: a financial investment by Tasly in Pharnext; the development of a new pipeline of synergistic combinations through a shared platform; and the license of Pharnext’s lead product for the Chinese market. Pharnext has requested Euronext to resume trading on its stock exchange effective as of Euronext Paris market opening on Wednesday May 10th, 2017 at 9:00am CEST. As a reminder, trading was suspended, as requested by the company and in agreement with the AMF (French Market Authority), on Tuesday May 9th, at 2:30pm (CEST). The above-mentioned major agreement is composed as follows: “This strategic partnership with Tasly is a major milestone: it confirms the global interest in and the value of our innovative technology platform, PLEOTHERAPY™. This partnership will provide access to new markets and new indications for Pharnext technology and products, while also integrating components of modernized traditional Chinese medicine,” said Prof. Daniel Cohen, M.D., Ph.D., Co-Founder and CEO of Pharnext. “We are very pleased and honored to collaborate with Tasly, a visionary company with an impressive history of revolutionizing the use of traditional Chinese medicine in a modernized form.” “We are very pleased to enter into a meaningful collaboration with Pharnext,” said Mr. Yan Kaijing, Chairman of Tasly Pharmaceuticals. “The joint-venture we are creating has the potential to generate a robust pipeline of new therapeutics. This partnership allows us to secure a significant equity interest in Pharnext, as well as the Chinese commercialization rights for their lead asset for Charcot-Marie-Tooth Type 1A disease. We will rely on Tasly's advantages of its existing biomedical R&D platform and access to the Chinese hospital network; as well as Pharnext’s remarkable drug R&D technological know-how to develop high-potential drug combinations, addressing important unmet medical needs. Based on biological disease network pharmacology, this partnership will exploit the immense potential of modernized Chinese traditional medicine, characterizing in a novel and precise way the mechanism of action of each combination we will develop.” Pharnext is an advanced, clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team. The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287). Tasly Pharmaceutical Group Co., Ltd. was listed on Shanghai Stock Exchange in August 2002 (Stock Code 600535). The company concept is "To share the joy of health with all” and the company mission “To improve human life and quality of life”. Tasly is committed to promoting the integration of Traditional Chinese Medicine (TCM) with modern medical and pharmaceutical technologies. It is also committed to building the first international brand of modernized TCM. “To become the global innovation leader of modern TCM and the scientific standard maker of modern TCM” is our target. To achieve this goal, Tasly will strive to bring modernized TCM to international pharmaceutical standards. To support its development strategy of “Comprehensive Internationalization”, Tasly has set up a complete manufacturing chain which respects international guidelines and exploits intelligent manufacturing system. Based on its ”Two Wheel of Innovation and Capitalization” strategy, Tasly has developed several core competitive advantages, such as its R&D model, its multi-level product system, its multi-dimensional patent protection system as well as its commercial and marketing network. The investment of €20 million by Tasly in Pharnext will be in two forms: €5 million in shares, at a price of €12.5 per share, and €15 million in convertible bonds (CB), paid at a rate of approximately 5%, and automatically converted at a price of €13 per share once the price has exceeded this value, on average, for 3 consecutive months. Tasly will also have the opportunity to convert their CB at a price of €13 per share at any time if the price is below this value. In the event of non-conversion at the end of 3 years, the CB would be, at the option of Pharnext, either repaid or converted at the market price with a discount of 20%. For clinical development and commercialization phases, Tasly and Pharnext will benefit from licenses with respect to the following a priori guidelines: These licenses will be granted to Pharnext and / or Tasly on payment to the JV of a share of the platform research costs, and a term repayment on sales or realized income. Tasly will ensure funding of the JV at its inception, with a cash contribution of 70 million RMB (€9.3 million) for new research and at least as much for the development of PXT3003 in the Chinese market. The license to the JV of the drug candidate PXT3003 for Charcot-Marie-Tooth Type 1A disease in the Chinese market will result in an upfront payment by the JV to Pharnext of €2 million. The closing of these 3 agreements is expected to take place around the end of June 2017.


Pharnext ist ein fortschrittliches biopharmazeutisches Unternehmen auf Klinikebene, das durch renommierte Wissenschaftler und Unternehmer, einschließlich Prof. Daniel Cohen, einen Vorreiter der modernen Genomik, gegründet wurde. Pharnext verfügt über zwei Leitprodukte in der klinischen Entwicklung. PXT3003 ist momentan in einer internationalen Phase-3-Studie zur Behandlung der Krankheit Charcot-Marie-Tooth Typ 1A und profitiert vom Status als Orphan-Arzneimittel in Europa und den USA. PXT864 hat zu positiven Ergebnissen in Bezug auf die Krankheit Alzheimer in Phase 2 geführt. Pharnext ist mit PLEOTHERAPY™ Vorreiter bei der Entdeckung neuer Arzneimittel. Das Unternehmen erfasst und entwickelt synergetische Kombinationen neu positionierter Arzneimittel bei niedrigen Dosierungen. Diese PLEODRUG™ bieten mehrere Schlüsselvorteile an: Effizienz, Sicherheit und geistiges Eigentum einschließlich mehrerer bereits bewährter patentierter Produkte und Verbindungen. Das Unternehmen wird durch ein erstklassiges Wissenschaftsteam unterstützt. Tasly Pharmaceutical Group Co., Ltd. wurde im August 2002 an der Shanghai Stock Exchange notiert (Stock Code 600535). Das Konzept des Unternehmens lautet „To share the joy of health with all” (Die Freude der Gesundheit mit allen teilen) und die Unternehmensmission „To improve human life and quality of life” (Das menschliche Leben und die Lebensqulität verbessern). Tasly setzt sich für die Förderung der Integration Traditioneller Chinesischer Medizin (TCM) mit modernen medizinischen und pharmazeutischen Technologien ein. Des Weiteren engagiert es sich für die Bildung der ersten internationalen Marke modernisierter TCM. „Der globale Innovationsführer moderner TCM und der wissenschaftliche Schreiber von Standards der modernen TCM zu werden", ist unser Ziel. Um dies zu erreichen, strebt Tasly danach, modernisierte TCM zu internationalen pharmazeutischen Standards zu machen. Zur Unterstützung seiner Entwicklungsstrategie „Comprehensive Internationalization” (umfassende Internationalisierung), hat Tasly eine komplette Herstellungskette aufgebaut, die internationalen Richtlinien entspricht und ein intelligentes Herstellungssystem nutzt. Auf der Grundlage seiner Strategie „Two Wheel of Innovation and Capitalization" (zwei Räder der Innovation und Kapitalisierung), hat Tasly mehrere zentrale Wettbewerbsvorteile entwickelt, wie sein Forschungs- und Entwicklungsmodell, sein mehrschichtiges Produktsystem, sein multidimensionales Patentschutzsystem sowie sein Vertriebs- und Marketingnetzwerk. Die Investition in Höhe von 20 Millionen Euro von Tasly in Pharnext wird auf zwei Wegen erfolgen: 5 Millionen Euro in Aktien zu einem Preis von 12,50 Euro pro Aktie und 15 Millionen Euro in Wandelschuldverschreibungen, die in Raten von ca. 5% gezahlt und zu einem Preis von 13 Euro pro Aktie umgewandelt werden, wenn der Preis diesen Wert durchschnittlich drei aufeinanderfolgende Monate lang übersteigt. Tasly wird auch die Möglichkeit haben, jederzeit seine Wandelschuldverschreibungen zu einem Preis von 13 Euro pro Aktie umzuwandeln, wenn der Preis unter diesem Wert liegt. Sollte nach drei Jahren keine Umwandlung erfolgt sein, werden die Wandelschuldverschreibungen nach Wahl von Pharnext entweder zum Marktpreis mit einem Abschlag von 20% zurückgezahlt oder umgewandelt. Die Lizenz für das Gemeinschaftsunternehmen in Bezug auf den Arzneimittelkandidaten PXT3003 für die Krankheit Charcot-Marie-Tooth Typ 1A auf dem chinesischen Markt wird in Form einer Vorauszahlung durch das Gemeinschaftsunternehmen an Pharnext in Höhe von 2 Millionen Euro geleistet.

Loading Shanghai Stock Exchange collaborators
Loading Shanghai Stock Exchange collaborators